Shots: The approval is based on the results of P-III PARADIGMS study assessing Gilenya (0.5mg/ 0.25mg, qd) vs Extavia (interferon beta-1a, qw) in 215 patients with MS aged 10 to […]readmore
Tags : PARADIGMS study